Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban.
Anticoagulants such as low molecular weight heparins (LMWH; e.g. enoxaparin) and black triangle downfondaparinux are cost-effective measures for reducing the likelihood of venous thromboembolism (VTE) in patients undergoing surgery.1 black triangle downDabigatran etexilate (Pradaxa-Boehringer Ingelheim)2 and black triangle downrivaroxaban (Xarelto - Bayer) are fixed-dose oral anticoagulants licensed in the European Union (EU) for the prevention of VTE in adults who have undergone or are undergoing elective replacement of the hip or knee joints.2,3 Here, we consider their place for these indications.
D000328:Adult; D000925:Anticoagulants / Q000191:economics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D000069604:Dabigatran; D006801:Humans; D009025:Morpholines / Q000191:economics / Q000627:therapeutic use*; D011725:Pyridines / Q000191:economics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000069552:Rivaroxaban; D013876:Thiophenes / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000191:economics / Q000517:prevention & control*
D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D011725:Pyridines; D013876:Thiophenes; D000069552:Rivaroxaban; D000069604:Dabigatran